India Pediatric Drugs And Vaccines Market Future Outlook To 2021: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit How the Pediatric Drugs and Vaccines Market is Positioned in India? India, a home of the largest pediatric population of the world and also has the highest number of annual child births in the world. However, almost 80-90% of the drugs used in children presently have never been studied for their efficacy in pediatric population. In India, results of the studies conducted in adult population are extrapolated for use in children. There are no specific medicine development regulations for pediatrics. Indian clinical practice relies heavily upon safety and efficacy data published in other developed countries or on inference from adult dosing. India pediatric drugs and vaccine market has witnessed tremendous growth in the last five years largely due to high number of annual births recorded at around ~ million, launch of generic formulations of several pediatric drugs including flavored TB drugs, inclusion of several vaccines in the national immunization schedule of the country and inclining coverage of children vaccination under national immunization schedule. The market for pediatric drugs and vaccine in India has been dominated by pediatric drugs, driven by the availability of large portfolio of drugs for treatment of several diseases as compared to a limited number of vaccines for prevention of some infectious diseases. High efficacy of vaccines has ensured prevention against diseases by virtue of few doses of vaccines. On the other hand, repeated incidence of some or the other non-vaccine preventable medical conditions coupled with comparatively heavy requirement of drug doses have resulted in a far greater usage of drugs. India pediatric drugs and vaccine market has grown at an overwhelming pace in the last five years, exhibiting growth at a CAGR of ~% during the period FY’2011 to FY’2016 from INR ~ billion in FY’2011 to INR ~ billion in FY’2016. How has the Pediatric Drugs Segment Performed? About ~% of child mortality is registered in the country. Respiratory diseases including pneumonia and tuberculosis are other commonly treatable conditions for which drugs find extensive usage in the country. Nearly ~ million children are reported to die due to pneumonia every year. Owing to less prevalence of lifestyle diseases amongst pediatric population, market share of drugs meant for management of diseases has been low. Drug meant for management of diseases are typically chronic diseases, particularly degenerative non-communicable diseases (NCDs) such as chronic respiratory diseases, cardiovascular diseases, cancer, HIV/AIDS and diabetes amongst others. Anti-infectives were the most frequently prescribed drug class by pediatricians, with over ~% of the prescriptions had some form of prescribed antibiotics. This is due to the wide scale prevalence of children being affected by respiratory diseases or some sort of microbial infections at regular basis. Anti-histamines are drugs used for the treatment of allergies. Owing to high occurrence of allergies amongst children, anti-histamines are next best selling drug class. Commonly prescribed anti-histamines include chlorphenamine, dexamethasone, epinephrine, hydrocortisone and prednisolone. In India, about ~% of children aged between 5-11 years are known to suffer from asthma and the prevalence is expected to rise further with growing industrialization and changing biodiversity. What is the Scenario of the Pediatric Vaccines Segment? India has emerged as the leading vaccine producer in the world, in terms of doses of vaccines produced, and has about ~ major vaccine manufacturing facilities across the country. Vaccines manufactured in these facilities are offered in both national and international market (over 150 countries). With over ~ million births every year, the domestic market for vaccines in India is huge. The country has been self sufficient in meeting the domestic needs, with private sector responsible for providing a large part of the supply needs. However, India lacks in coverage rate of basic vaccines. The Indian domestic market for Universal Immunization Programme (UIP) alone is over ~ million doses. The R&D cost of UIP vaccines is minimal; however, the non-UIP vaccines involve technology licensing, R&D, infrastructure and operational costs. In addition, stringent regulatory requirements for the licensing of newer vaccines, add up to the cost. More than ~% of all measles vaccines used globally are produced in India. Moreover, Indian firms are big suppliers to the UN agencies, accounting in between ~% and ~% of the vaccines purchased by organization every year. India has emerged as a major vaccine producer in recent times by focusing on geographical regions where vaccines are not funded by the UN or charitable organizations and strategic ties with UN and government agencies to supply vaccines at affordable prices. The Indian pediatric market for vaccines has grown at a remarkable CAGR of ~% during the period FY’2011-FY’2016. The growth was attributed to some crucial vaccines (polio, hepatitis B, MMR and BCG) manufactured by Indian companies constantly featured in WHO’s prequalified list coupled with the fact that Indian companies (Serum Institute of India, Bharat Biotech, Panacea Biotec) acted as major suppliers of vaccines to WHO, UNICEF, PATH and other UN agencies. The market for pediatric vaccines grew from INR ~ billion in FY’2011 to INR ~ billion in FY’2016. Companies Cited in the Report List of Major Companies Companies Covered in the Report Sun Pharmaceuticals Lupin Pharmaceuticals Cipla Dr. Reddy’s Laboratories Major Players Abbott India Serum Institute of India Panacea Biotec Bharat Biotech GSK Pharmaceuticals Biological E Limited Key Factors Considered in the Report Comprehensive analysis of the India pediatric drugs and vaccines market and its segments Listed major players and their offerings Identified major developments in last few years and assessed the future growth of the industry Government initiatives taken to stimulate the growth of the market. For more coverage click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/india-pediatric-drug-vaccine-market/81319-91.html Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249 Tags: Attenuated vaccines Industry Developments, Conjugate Vaccines Contribution India, Dosage, Drug Information, Drug Pipeline Pediatric Drug, Future Growth India Pediatric Vaccine, Generic Pediatric Drugs Sales, India Anti-infectives Market Growth, India Inactivated Vaccines Industry Size, India Pediatric Drugs Market, Indian Pediatrics Market, Kids Antihistamines Market Sales, Lupin Pediatric Drug Revenue, Market Share Sun Pharmaceuticals Pediatric Drug, New Drug Launches India Pharma Sector, Number of Pediatrician Statistics, Pediatric Drug Development, Pediatric Drug Market Industry Size, Pediatric Drugs Revenue Pharma Sector, Pediatric tuberculosis drug Market, Pediatric Vaccine Serum Institute of India, Recombinant Vaccines Market Competition, Revenue Cardiovascular Drugs India, Side Effects, Subunit Vaccines Sales India, Toxoid Vaccines Market share, Trends Pediatric Vaccine Market, Vaccine Clinical Trials India, Vaccines Market Growth India